2019 BCOP Education

Upcoming Events


Check out the latest edition of HOPA News!


Latest Discussions

HOPA Bulletin

  • Epizyme has been pursuing a novel target in multiple myeloma, and now it has reported positive data from mouse studies for a potential first-in-class therapy. The drug, dubbed EPZ-719, targets the enzyme SETD2, which the company's scientists believe helps support a cancer-causing mutation that's found in about 15% of multiple myeloma cases. EPZ-719 significantly inhibited tumor growth in mice with or without the driver mutation, according to data presented at the European Hematology Association virtual congress.

Getting Started

Check out our user guide for further information.

Connect With Us